Amyris Co-founder Recognized for Role in Engineering Microbes to Produce
Lower Cost Anti-malarials and High-performing Renewable Biofuels;
TR35 2007 Recipients to be Honored at Technology Review's Emerging
Technologies Conference at MIT
EMERYVILLE, Calif., Aug. 15 /PRNewswire/ -- Amyris Biotechnologies is pleased to announce that Neil Renninger, Ph.D., co-founder and senior vice president of development, has been recognized by Technology Review magazine as one of the world's top innovators under the age of 35. Renninger is being recognized for his contributions to the development of a technology platform for engineering metabolic pathways in microbes to make high-value compounds that help address major global health and energy challenges.
This technology was initially applied to reduce the production cost of artemisinin-based anti-malarial drugs. The research and development team co-led by Renninger applied Amyris' technology platform to develop a microbially-derived artemisinin precursor which is expected to reduce the cost of artemisinin to a fraction of its current cost. In the next application of this technology, Renninger and his team identified high-performing hydrocarbon-based transportation biofuels that can be made using similarly engineered microbes. The resulting fuels will be environmentally friendly, cost-effective, and compatible with current engines and distribution infrastructure.
Selected from hundreds of nominees by a panel of expert judges and the editorial staff of Technology Review, the TR35 is an elite group of accomplished young innovators recognized as having the potential to profoundly impact the world, based on their innovation in their respective areas.
"Neil's work will change the lives of generations to come, both in the
fight against malaria and in creating sustainable energy alternatives in
biofuels," said John Doerr of Kleiner Perkins Caufield & Byers and member
|SOURCE Amyris Biotechnologies|
Copyright©2007 PR Newswire.